• In late June 2026, Relay Therapeutics, Inc. was added to multiple Russell Growth and Small Cap benchmarks, including the Russell 2000 Growth, Russell 2500 Growth, Russell 3000 Growth, Russell 3000E Growth, and Russell Small Cap Comp Growth indices.
• This broad inclusion across several Russell growth-oriented and small-cap indices increases the company’s visibility with index-tracking funds and benchmark-aware institutional investors.
• Next, we’ll examine how Relay Therapeutics’ broad Russell Growth index inclusion shapes its investment narrative for existing and prospective shareholders.

Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

What Is Relay Therapeutics' Investment Narrative?

To own Relay Therapeutics today, you have to believe that its pipeline, led by zovegalisib with Breakthrough Therapy Designation, can ultimately translate scientific promise into commercially meaningful drugs despite ongoing losses and dilution. The recent wave of Russell growth and small cap index additions mainly affects who might own the stock rather than what really drives value: clinical outcomes, regulatory decisions and future partnering or financing terms. Index inclusion could modestly deepen liquidity and broaden the shareholder base at a time when the company has just raised US$175,000,000 and expanded its authorized share count, but it does not directly change the near term execution risk around late stage trial design or future capital needs. After a very large one year total return, those risks arguably matter more than ever.

However, one risk that stands out is how future equity raises could affect existing holders. Our valuation report unveils the possibility Relay Therapeutics' shares may be trading at a premium.

Exploring Other Perspectives

With just one Simply Wall St Community fair value estimate clustered at about US$24.82, you are seeing a very tight band of expectations. Set that against Relay’s recent index-driven visibility and ongoing cash burn and it becomes clear why different market participants may reach very different conclusions about what the stock is worth.

Explore another fair value estimate on Relay Therapeutics - why the stock might be worth just $24.82!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Relay Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Relay Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Relay Therapeutics' overall financial health at a glance.

Curious About Other Options?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 15 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Find 45 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.